Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vedolizumab induction and maintenance therapy in Japanese patients with moderate to severe Crohn's disease
2019-001199-12Phase 3
- Sponsor
- Takeda
- Start
- May 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Crohn's disease comparing Entyvio with Placebo (2 arms). Primary endpoint: CDAI-100 response.
02
Drugs
vedolizumab
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on 2019-001199-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-001199-12.